Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Hepatocellular carcinoma (HCC)is the most frequent primitive tumour of the liver.

Recently, several research studies reported that 11C-choline PET has shown a high detection rate of well differentiated HCC, which is an early stage of primary liver cancer. The aim of this study was to prospectively evaluate the diagnostic accuracy of 11C-choline PET-CT to detect HCC in cirrhotic or non cirrhotic patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Commissariat A L'energie Atomique
• Collaborator: Assistance Publique - Hôpitaux de Paris
• Treatments: Choline

Criteria

Inclusion Criteria:

• Patients up to 18 years old with

• Patients with suspicion hepatocellular carcinoma on conventional imaging(hepatic ultrasonography, abdominal computed tomography, dynamic resonance magnetic)and/or on alpha fetoprotein measurement

• Patients with suspicion recurrence of hepatocellular carcinoma on conventional imaging(hepatic ultrasonography, abdominal computed tomography, dynamic resonance magnetic)and/or on alpha fetoprotein measurement

• Patients which perform two conventional imaging techniques, consisting in dynamic magnetic resonance imaging (MRI) and computed tomography (CT)and must have an alpha fetoprotein measurement

• Patients which perform 18F-FDG PET-CT

• Informed Consent Form signed and dated by patients

• Patients which are "Security Social" affiliated

Exclusion Criteria:

• Pregnant or suckling women

• Women able to procreate, without efficient birth control

• Patients with an other tumoral disease

• Patients with chemotherapy or surgery from less than four weeks

• Patients with radiotherapy from less four months